Prognosis in Patients With Sentinel Node–Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria
Augustinus P. T. van der Ploeg(Erasmus MC Cancer Institute), Alexander M.M. Eggermont(University Medical Center Utrecht), Cornelis Verhoef(Erasmus MC Cancer Institute), Christiane Voit(Humboldt-Universität zu Berlin), Mari F.C.M. van den Hout(Erasmus MC Cancer Institute), Wanda Michej(European Organisation for Research and Treatment of Cancer), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Harald J. Hoekstra(University Medical Center Groningen), Angana Mitra(Erasmus MC Cancer Institute), Zbigniew Nowecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Omgo E. Nieweg(The University of Sydney), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Alexander C. J. van Akkooi(The University of Sydney), Julia Newton‐Bishop(University of Leeds), Caroline Robert(Institut Gustave Roussy), F Cataldo(Erasmus MC Cancer Institute), Martin Cook(Royal Surrey NHS Foundation Trust), Iris M. C. van der Ploeg(Erasmus MC Cancer Institute), Paul A.M. van Leeuwen(Erasmus MC Cancer Institute), Alan Spatz(Jewish General Hospital)
Cited by 209
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k